Mod­er­na part­ners on non-vi­ral gene ther­a­py with Gen­er­a­tion Bio af­ter swing­ing gene edit­ing deals

Mod­er­na has inked a five-year part­ner­ship with gene ther­a­py biotech Gen­er­a­tion Bio, it an­nounced Thurs­day morn­ing, wad­ing deep­er in­to the ge­net­ic med­i­cines space as it nav­i­gates be­yond its vac­cine work.

Mod­er­na will pay Gen­er­a­tion Bio $40 mil­lion up­front and in­vest an­oth­er $36 mil­lion in­to the gene ther­a­py biotech. In ex­change, Mod­er­na can li­cense Gen­er­a­tion Bio’s non-vi­ral gene ther­a­py plat­forms for two im­mune cell pro­grams and two liv­er pro­grams, with an op­tion for a fifth pro­gram. Mod­er­na will fund all the re­search work un­der the part­ner­ship, and could be on the hook for mile­stone, fee and roy­al­ty pay­ments to­tal­ing up to $1.8 bil­lion, a com­pa­ny spokesper­son tells End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER